 Shares of genetic muscle disease concern Dyne Therapeutics, Inc. have enjoyed a recent bounce on the back of good news from a rival, more than tripling in price. The recent news somewhat validatedde-risked its oligonucleotide approach to treating muscle diseases, as its first two programs entered the clinic in September 2022. 